Urosphere will be attending the AACR Annual Meeting 2026, taking place April 17–22, 2026, in San Diego, CA.
Our team looks forward to meeting you at Booth #5036, where experts from both Urosphere and XenTech will be available to showcase how our complementary expertise in patient-derived xenografts (PDX) and organoid models supports translational oncology research and accelerates preclinical decision-making.
As sister companies, Urosphere and XenTech will be joining forces during the meeting. This joint presence reflects the strong synergy between our teams, offering an integrated and predictive preclinical approach from organoids to PDX models.
During the meeting, our scientists will present 6 research posters highlighting new insights into drug resistance mechanisms and immunotherapy evaluation:.
- Poster #2154:Bidan N. et al., Modeling olaparib resistance in prostate cancer PDXs to elucidate PARP inhibitor escape mechanisms.
- Poster #2958:Decaup E. et al., P-glycoprotein (ABCB1) overexpression confers resistance to the antibody-drug conjugate Enfortumab vedotin in EV-resistant organoid and PDX models.
- Poster #7526:Deas O. et al., Breast cancer organoids as a complementary preclinical model to PDX, enabling immunotherapy evaluation.
- Poster #4879:Decaup E. et al., Bladder cancer organoids as a translational models to model disease biology and assess new therapies.
- Poster #2163 – Indersie E et al. Triple-negative breast cancer PDX models with acquired resistance to Enhertu®: A preclinical platform to uncover mechanisms of escape
- Poster #2164 – Indersie E et al. Breast cancer PDX models with acquired resistance to olaparib: A preclinical platform to uncover mechanisms of PARP inhibitor escape